Bcl10 Antibody

Flow cytometry: 0.5-1ug/million cells,Immunofluorescence: 1-2ug/ml,Immunohistochemistry (FFPE): 0.5-1ug/ml for 30 min at RT

The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the recombinant Bcl10 antibody to be titered up or down for optimal performance.

1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.

Bcl10, with an N-terminal caspase recruitment domain (CARD), is found in a number of apoptotic regulatory molecules. It was identified through its direct involvement in t(1;14) of mucosa-associated lymphoid tissue (MALT) lymphoma. Expression of Bcl10 was shown to induce NFkB activation in a NIK-dependent pathway. This antibody labels subpopulations of normal B and T cells and is a useful tool for the sub-classification of lymphomas. In MALT lymphomas with the t(1;14) translocation, while 55% of MALT lymphomas lacking this translocation exhibited the same labeling pattern, although at a much lower level.

Purified

0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide

8915

A portion of amino acids 122-168 from the human protein was used as the immunogen for this recombinant Bcl10 antibody.

This recombinant Bcl10 antibody is available for research use only.

Nuclear and cytoplasmic

Protein A affinity chromatography

Human